However, resistance in BRAF-mutated melanoma appears to develop at 6 to 7 months (Long, Stroyakovskiy, & Gogas, 2014), so pembrolizumab may be an option upon recurrence (Robert et al., 2014). This evidence concerns the gene BRAF and melanoma.